Stopping douching products after menstruation may reduce risk of bacterial vaginosis.
Women who regularly use douching products to cleanse the vagina after menstruation may reduce the risk of bacterial vaginosis (BV) by stopping the practice, according to research published in the June issue of the American Journal of Obstetrics and Gynecology.
Rebecca M. Brotman, PhD, of Johns Hopkins Bayview Medical Center in Baltimore, and colleagues conducted a study of 39 women who reported using douching products. The women used the products for 4 weeks, then stopped for a 12-week observation period, after which they decided whether to resume douching or continue cessation for the final 4 weeks of the study. Twice-weekly self-collected vaginal samples were taken and a final sample was collected during the last week.
During the douching cessation phase, the odds of developing BV was 0.76 compared with the odds during the initial douching stage, the investigators found. For women who had reported douching to cleanse the vagina after menstruation, cessation significantly reduced the risk of BV (adjusted odds ratio, 0.23).
Brotman RM, Ghanem KG, Klebanoff MA, et al. The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. Am J Obstet Gynecol. 2008;198:628.e1-628.e7.
Thinner endometrial thickness linked to higher placenta accreta spectrum risk
November 29th 2024A recent study reveals that reduced endometrial thickness significantly increases the risk of placenta accreta spectrum disorders in women without prior cesarean deliveries using assisted reproductive technology.
Read More
Emerging multiplex UTI testing drives Medicare costs amid increased utilization
November 27th 2024A recent study found a sharp rise in Medicare claims for multiplex urinary tract infection testing from 2016 to 2023, underscoring a significant financial impact and the need for further research into its clinical benefits.
Read More
Reduced cost-effectiveness reported from HPV vaccination in mid-adults
November 27th 2024A recent study highlights the reduced cost-effectiveness of expanding human papillomavirus vaccination to adults aged 27 to 45 years compared to younger groups, though targeted strategies for high-risk subgroups indicate benefits.
Read More